News | November 30, 2021
Conference highlights opportunities in the nursing profession
This collaborative nursing conference generated a positive dialogue on how the healthcare space of nursing has evolved in the past year
This collaborative nursing conference generated a positive dialogue on how the healthcare space of nursing has evolved in the past year
Vaccine effectiveness of complete vaccination against the moderate-to-severe disease was at 81 per cent
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
ALASTIN’s patented, differentiated technology and products are highly synergistic with Galderma’s premium portfolio
It’s a two-dose vaccine administered 28 days apart
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
Subscribe To Our Newsletter & Stay Updated
